Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Research and Development — Contract with customer, transaction price

Similar metrics at other companies

Ionis Pharmaceuticals logo
IONSResearch And Development Revenue — Revenue
$138.28M+149%
Nuvation Bio logo
NUVBResearch And Development Service Revenue — Revenue
$700K-63.2%
BridgeBio Pharma logo
BBIOResearch and Development Services — Contract with customer, liability
$2.7M—
IDEAYA Biosciences, Inc. logo
IDYAResearch And Development Services — Revenue Remaining Performance Obligation
$155.3M—
Nuvation Bio logo
NUVBResearch And Development Service Revenue — Contract With Customer Liability Revenue Recognized
$8.6M+359%
IQVIA logo
IQVResearch & Development Solutions — Revenue
$2.4B+6.2%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:ContractWithCustomerTransactionPrice.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's research and development — contract with customer, transaction price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's research and development — contract with customer, transaction price?
BioCryst Pharmaceuticals (BCRX) reported research and development — contract with customer, transaction price of $20.67M in Q1 2026.
What does research and development — contract with customer, transaction price mean?
This metric represents the total transaction price allocated to performance obligations satisfied through research and development services provided to external customers. It captures the revenue generated from collaborative research agreements, licensing arrangements, or contract research services where the company applies its scientific expertise to advance third-party drug development programs. This figure serves as a key indicator of the company's ability to monetize its proprietary research capabilities and intellectual property through strategic partnerships.